↓ Skip to main content

Dove Medical Press

Current status of NADPH oxidase research in cardiovascular pharmacology

Overview of attention for article published in Vascular Health and Risk Management, July 2013
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (69th percentile)
  • Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

twitter
2 X users
patent
1 patent

Citations

dimensions_citation
46 Dimensions

Readers on

mendeley
78 Mendeley
Title
Current status of NADPH oxidase research in cardiovascular pharmacology
Published in
Vascular Health and Risk Management, July 2013
DOI 10.2147/vhrm.s33053
Pubmed ID
Authors

Ezequiel Álvarez, Rodiño-Janeiro, Paradela-Dobarro, Castiñeiras-Landeira, Raposeiras-Roubín, Gonzalez-Juanatey

Abstract

The implications of reactive oxygen species in cardiovascular disease have been known for some decades. Rationally, therapeutic antioxidant strategies combating oxidative stress have been developed, but the results of clinical trials have not been as good as expected. Therefore, to move forward in the design of new therapeutic strategies for cardiovascular disease based on prevention of production of reactive oxygen species, steps must be taken on two fronts, ie, comprehension of reduction-oxidation signaling pathways and the pathophysiologic roles of reactive oxygen species, and development of new, less toxic, and more selective nicotinamide adenine dinucleotide phosphate (NADPH) oxidase inhibitors, to clarify both the role of each NADPH oxidase isoform and their utility in clinical practice. In this review, we analyze the value of NADPH oxidase as a therapeutic target for cardiovascular disease and the old and new pharmacologic agents or strategies to prevent NADPH oxidase activity. Some inhibitors and different direct or indirect approaches are available. Regarding direct NADPH oxidase inhibition, the specificity of NADPH oxidase is the focus of current investigations, whereas the chemical structure-activity relationship studies of known inhibitors have provided pharmacophore models with which to search for new molecules. From a general point of view, small-molecule inhibitors are preferred because of their hydrosolubility and oral bioavailability. However, other possibilities are not closed, with peptide inhibitors or monoclonal antibodies against NADPH oxidase isoforms continuing to be under investigation as well as the ongoing search for naturally occurring compounds. Likewise, some different approaches include inhibition of assembly of the NADPH oxidase complex, subcellular translocation, post-transductional modifications, calcium entry/release, electron transfer, and genetic expression. High-throughput screens for any of these activities could provide new inhibitors. All this knowledge and the research presently underway will likely result in development of new drugs for inhibition of NADPH oxidase and application of therapeutic approaches based on their action, for the treatment of cardiovascular disease in the next few years.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 78 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 1%
France 1 1%
Unknown 76 97%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 16 21%
Researcher 12 15%
Student > Master 10 13%
Student > Bachelor 9 12%
Other 5 6%
Other 6 8%
Unknown 20 26%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 14 18%
Medicine and Dentistry 13 17%
Agricultural and Biological Sciences 13 17%
Pharmacology, Toxicology and Pharmaceutical Science 7 9%
Neuroscience 5 6%
Other 5 6%
Unknown 21 27%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 October 2021.
All research outputs
#6,764,961
of 22,715,151 outputs
Outputs from Vascular Health and Risk Management
#242
of 752 outputs
Outputs of similar age
#57,529
of 194,642 outputs
Outputs of similar age from Vascular Health and Risk Management
#5
of 22 outputs
Altmetric has tracked 22,715,151 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 752 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.8. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 194,642 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 77% of its contemporaries.